Aarti Pharmalabs Ltd promoter group reduced its shareholding by 3.20% to 39.66% between September 19, 2025, and September 21, 2026.

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The selling entities included Gloire Trusteeship Services Pvt Ltd (Lotus Family Trust) and other promoters within the promoter group.

Breakdown of Shareholding Changes

The promoter group’s total holding decreased from 42.88% to 39.66% during the specified period. The net disposal involved a combination of sales by the trust and other promoters, partially offset by minor acquisitions.

Transaction Details

The transactions were executed through both open market and off-market modes. The specific movements in voting rights shares were as follows:

• Gloire Trusteeship Services Pvt Ltd sold 6,24,500 shares, representing 0.69% of the capital.
• Other promoters sold 24,78,539 shares, accounting for 2.73% of the capital.
• Other promoters acquired 2,00,064 shares, adding back 0.22% to their holding.

The total equity share capital of the company stood at 9,06,79,813 shares after the transactions, up from 9,06,41,224 shares prior to the sale period.

What the Numbers Show

The complete exit of Gloire Trusteeship Services Pvt Ltd from its 0.69% stake indicates a full divestment by this specific trust entity. Meanwhile, the broader promoter group retained a significant majority control at 39.66%, suggesting the reduction was likely for liquidity or strategic realignment rather than a loss of control.

Aarti Pharmalabs Limited declared a final dividend of ₹2 per equity share for FY26 during its 7th Annual General Meeting held on September 22, 2026. The announcement coincided with the release of FY26 financial results, which showed a decline in profitability.

The company's standalone Profit After Tax (PAT) stood at ₹1,762 crore, a decrease of 31.5% from ₹2,573 crore in FY25. Operational revenue grew marginally by 1.5% to ₹17,976 crore, while EBITDA contracted by 4.8% to ₹4,061 crore. The drop in net profit was driven by higher depreciation, finance costs, and foreign exchange losses.

Leadership restructuring approved

Shareholders passed special resolutions to alter the designations of key board members effective October 1, 2026. Rashesh C. Gogri was appointed as Managing Director, transitioning from his previous role as Non-Executive Director. Concurrently, Hetal Gogri Gala was re-designated from Managing Director to Whole-time Director.

Additionally, Rajendra Gogri, who was liable to retire by rotation, did not offer himself for re-appointment. The shareholders resolved that the vacancy created on the Board would not be filled.

Financial performance overview

The audited standalone financial statements for FY26 were adopted without qualifications. The following table summarizes the key standalone financial metrics:

The consolidated operational revenue declined by 14.0% to ₹18,194 crore, with consolidated PAT falling 35.9% to ₹1,747 crore. The company noted that recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability, with previous year figures restated accordingly.

Strategic investments and outlook

Aarti Pharmalabs continues to expand its manufacturing capacity. The Atali greenfield project in Gujarat, with an estimated investment of ₹400 crore, has ~80% capacity operationalized by Q4FY26. Additionally, the Tarapur brownfield expansion, involving an investment of ₹210 crore, is expected to be operationalized in Q1FY27.

The company targets a 15-18% Revenue and EBITDA CAGR over the next 3-4 years. Key strategic initiatives include initiating R&D investment in TIDES (Peptides & Oligonucleotides) in FY27 and announcing capex for Atali Block 2 for specific CDMO/CMO projects.

What the numbers show

The divergence between standalone revenue growth (+1.5%) and the significant decline in PAT (-31.5%) highlights pressure on margins. While EBITDA margin contracted by 149 bps to 22.6%, the bottom-line impact was amplified by a 31.9% rise in depreciation and amortisation and an 83.2% surge in finance costs. Furthermore, a swing from a foreign exchange gain of ₹17 crore in FY25 to a loss of ₹332 crore in FY26 contributed significantly to the profit erosion.